Home/Filings/4/0001144204-19-000788
4//SEC Filing

Rombotis Spiro George 4

Accession 0001144204-19-000788

CIK 0001130166other

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 9:26 AM ET

Size

10.7 KB

Accession

0001144204-19-000788

Insider Transaction Report

Form 4
Period: 2019-01-03
Rombotis Spiro George
DirectorPresident & C.E.O.
Transactions
  • Award

    Option

    2019-01-03+15,62515,625 total
    Exercise: $1.74Exp: 2027-12-29Common Stock (15,625 underlying)
  • Award

    Option

    2019-01-03+14,37514,375 total
    Exercise: $1.56Exp: 2028-02-22Common Stock (14,375 underlying)
  • Award

    Option

    2019-01-04+508,198508,198 total
    Exercise: $0.71Exp: 2029-01-04Common Stock (508,198 underlying)
Footnotes (4)
  • [F1]These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
  • [F2]These securities were granted as part of the Issuer's annual compensation review to executive officers.
  • [F3]On December 29, 2017, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 15,625 shares.
  • [F4]On February 22, 2018, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 14,375 shares.

Issuer

Cyclacel Pharmaceuticals, Inc.

CIK 0001130166

Entity typeother

Related Parties

1
  • filerCIK 0001357396

Filing Metadata

Form type
4
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 9:26 AM ET
Size
10.7 KB